Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)
7.08
-0.11 (-1.53%)
Sep 10, 2026, 3:00 PM CST
SHA:603811 Revenue
Zhejiang Cheng Yi Pharmaceutical had revenue of 230.80M CNY in the quarter ending June 30, 2026, a decrease of -0.12%. This brings the company's revenue in the last twelve months to 827.47M, up 6.74% year-over-year. In the year 2025, Zhejiang Cheng Yi Pharmaceutical had annual revenue of 812.35M with 13.72% growth.
Revenue (ttm)
827.47M
Revenue Growth
+6.74%
P/S Ratio
3.86
Revenue / Employee
1.37M
Employees
604
Market Cap
3.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 812.35M | 97.98M | 13.72% |
| Dec 31, 2024 | 714.37M | 42.74M | 6.36% |
| Dec 31, 2023 | 671.63M | 16.65M | 2.54% |
| Dec 31, 2022 | 654.97M | -38.99M | -5.62% |
| Dec 31, 2021 | 693.96M | -64.17M | -8.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Guizhou Yibai Pharmaceutical | 1.56B |
| Nanjing Well Pharmaceutical Group | 1.40B |
| Huaren Pharmaceutical | 1.30B |
| Anhui Sunhere Pharmaceutical Excipients | 993.60M |
| PKU HealthCare Corp.,Ltd. | 972.17M |
| Baotou Dongbao Bio-Tech Co.,Ltd | 790.94M |
| Tibet AIM Pharm. | 684.45M |
| Chongqing Jiheng Pharmaceutical | 654.22M |